Skip to content

The Effect and Mechanisms of the Second-meal Phenomenon in Type 2 Diabetic Patients

The Effect and Mechanisms of the Second-meal Phenomenon in Type 2 Diabetic

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT01127997
Enrollment
12
Registered
2010-05-21
Start date
2010-03-31
Completion date
2010-08-31
Last updated
2010-08-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 Diabetes

Brief summary

Second-meal phenomenon denotes the effect of a prior meal in decreasing the rise in blood glucose after a subsequent meal. This phenomenon occurs in normal subjects while it is not clear whether it is also observed in type 2 diabetic patients. This study aims to define whether the second-meal phenomenon occurs in type 2 diabetic patients. We will also seek for the mechanism.

Interventions

None listed

Sponsors

The Catholic University of Korea
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
CROSS_SECTIONAL

Eligibility

Sex/Gender
ALL
Age
35 Years to 70 Years
Healthy volunteers
No

Inclusion criteria

* age 35-70 * HbA1c 6-8% * DM duration less than 5 yrs

Exclusion criteria

* type 1 DM, secondary DM, gestational DM * patients using insulin, TZDs * patients using corticosteroid, herb medication or other medications affecting glucose tolerance * renal dysfunction (Cr \> 1.5mg/dL) * hepatic dysfunction (LFT \> x 3UNL) * anemia (Hg \< 10g/dL) * ischemic heart disease, congestive heart failure * severe diabetic complication (CRF, CVA, PDR, gastroparesis) * infectious disease * malignancy * pregnant women

Design outcomes

Primary

MeasureTime frameDescription
Area under the curve of plasma glucose after meal3 monthsCompare the post-lunch AUC of glucose between two meal tolerance tests(one after having breakfast, one after not having breakfast)

Secondary

MeasureTime frameDescription
the mechanism of second-meal phenomenon3 monthsserum FFA, plasma insulin, C-peptide, incretin concentration will be measured

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026